論文・技術情報追加のお知らせ

1. Infection and infestation-related adverse events of biologics in psoriasis: insights from the food and drug administration adverse event reporting system (FAERS).

生物学的製剤使用時の感染リスクを評価

対象DB：FAERS

2. Comparative safety analysis of lacosamide and perampanel in epilepsy management: insights from FAERS database.

ラコサミドとペランパネルの副作用を比較

対象DB：FAERS

3. Fixed Drug Eruption and Generalized Bullous Fixed Drug Eruption: Insights from an Analysis of the FDA Adverse Event Reporting System.

固定薬疹の解析結果からの知見

対象DB：FAERS

4. Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database.

イバブラジンの副作用は女性に多く、初月に多発

対象DB：FAERS

5. Adverse events associated with Azithromycin and clarithromycin in adults aged >/=65: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database.

高齢者でアジスロマイシンはQT延長、クラリスロマイシンは薬物相互作用に注意

対象DB：FAERS

6. Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug-drug interactions through the FDA adverse event reporting system.

コルヒチンとスタチン併用は横紋筋融解症のリスク増加

対象DB：FAERS

7. Pancreatitis Associated With Teduglutide: A Disproportionality Analysis via the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

テドグルチド使用に膵炎のリスクあり、注意が必要

対象DB：FAERS

8. Neratinib safety evaluation: real-world adverse event analysis from the FAERS database.

ネラティニブの副作用を分析し、新たな情報を提供

対象DB：FAERS

9. Adverse events associated with SARS-CoV-2 neutralizing monoclonal antibodies using the FDA adverse event reporting system database.

抗SARS-CoV-2抗体の重要な医療事象を分析

対象DB：FAERS,KAERS,VAERS

10. Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System.

薬剤による性欲低下のリスクを分析

対象DB：FAERS

11. Real-world large sample assessment of drug-related dry eye risk: Based on the FDA adverse event reporting system database.

薬剤性ドライアイのリスクを分析

対象DB：FAERS

12. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.

KRAS(G12C)阻害薬の有害事象を分析

対象DB：FAERS

13. Herpes virus reactivation induced by abrocitinib: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.

アブロシチニブによるヘルペスウイルス再活性化のリスクは、女性に高く、デュピルマブ併用でリスク低下、バリシチニブ併用でリスク増加

対象DB：FAERS

14. A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine.

ビンカアルカロイドの副作用を分析し、特に血液・リンパ系への影響を示した

対象DB：FAERS

15. Characterization of Antineoplastic Agents Inducing Taste and Smell Disorders Using the FAERS Database.

抗癌剤による味覚・嗅覚障害のリスクを分析し、特にタンパク質キナーゼ阻害剤が関連していることを示した

対象DB：FAERS

16. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.

タファミジスの副作用をFAERSで分析、聴覚障害や高血圧など新たな副作用を特定

対象DB：FAERS

17. Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions.

免疫チェックポイント阻害剤とプロトンポンプ阻害剤の併用における薬剤相互作用を特定

対象DB：FAERS

18. Evaluation of Antipsychotic-Induced Neuroleptic Malignant Syndrome Using a Self-Organizing Map.

抗精神病薬のNMSリスクを自己組織化マップで可視化し、治療の参考にした

対象DB：JADER

19. Risk of Rhabdomyolysis Associated with Dexmedetomidine Use over the Past 10 Years: Insights from the EudraVigilance Database.

デクスメデトミジンはプロポフォールよりも横紋筋融解症のリスクが低い

対象DB：EudraVigilance

20. Association between complementary use of Goreisan (a Japanese herbal Kampo medicine) and heart failure readmission: A Nationwide propensity score-matched study.

五苓散は腎疾患患者の心不全再入院リスクを低減したが、全体では効果がなかった

対象DB：DPC

21. Comparison of High-Dose versus Low-Dose Trimethoprim-Sulfamethoxazole for Treating Pneumocystis jirovecii Pneumonia among Hemodialysis Patients: A Nationwide Database Study in Japan.

血液透析患者のPJP治療で高用量TMP-SMXは効果に差がなかった

対象DB：DPC

22. Risk stratification for cardiovascular disease based on prior coronary artery disease, cerebrovascular disease and type 2 diabetes mellitus.

糖尿病と脳血管疾患が心血管リスクを大幅に増加

対象DB：JMDC

23. Identifying individuals at high risk for dementia in primary care: Development and validation of the DemRisk risk prediction model using routinely collected patient data.

新しいモデルは認知症リスクを従来より高精度に予測

対象DB：CPRD

24. Lower Incidence of Dementia Following Cancer Diagnoses: Evidence from a Large Cohort and Mendelian Randomization Study.

がん生存者は認知症リスクが25％低いことが確認

対象DB：CPRD

25. The use of locum doctors in the NHS: understanding and improving the quality and safety of care.

NHSにおける代替医師の利用は増加し、組織面での改善が必要

対象DB：CPRD

26. Immediate allergies to chlorhexidine: A series of pediatric cases from the French pharmacovigilance database: Immediate allergies to chlorhexidine: series of pediatric cases from the French pharmacovigilance database.

小児のクロルヘキシジン即時アレルギー反応が過小評価されている

対象DB：FPVD

27. Comparative Diagnostic Accuracy of Nursing Delirium Screening Scale Versus Confusion Assessment Method for Postoperative Delirium: A Systematic Review and Meta-Analysis.

Nu-DESCとCAMの術後せん妄検出精度は不十分

対象DB：DeSC

28. Dose-dependent association between estimated glomerular filtration rate and the subsequent risk of depression: An analysis of a nationwide epidemiological dataset.

腎機能低下と抑うつリスクがeGFR65未満で増加

対象DB：DeSC